ICH Q13Continuous Manufacturing of Drug Substances and Drug Products

ICH Q13 was finalised at Step 4 in November 2022 — the first ICH guideline written specifically for continuous manufacturing (CM). It covers CM of small-molecule drug substances, small-molecule drug products (oral solids in particular), and therapeutic proteins. It explicitly excludes cell and gene therapies and does not cover ATMPs in continuous flow.

Q13 does not introduce a new regulatory framework. CM facilities are GMP facilities and must meet the same expectations — 21 CFR 210/211 in the US, EU GMP Part I in Europe — as batch facilities. What Q13 does is interpret those expectations for a process in which raw materials flow continuously through interconnected unit operations and finished product emerges continuously, rather than as discrete batches sitting on a floor between steps.

Q13 explicitly allows three approaches to defining a batch in CM, and any of them is acceptable provided it is justified and fixed in the control strategy and the batch record.

1. Quantity of material produced — for example, 200 kg of compressed tablets.
2. Quantity of input material processed — for example, the output produced from 200 kg of API fed to the line.
3. Run time at a defined steady state — for example, all material produced during a 48-hour run.

The batch definition matters because it determines what is sampled, what is released together, and how the batch record is structured. A run-time-defined batch may include short start-up and shut-down windows that are diverted as non-batch material; a quantity-defined batch may span multiple runs if the line is paused for maintenance.

In batch manufacturing, state of control is largely demonstrated by post-step QC testing and by validation of the unit operations. In CM, state of control is dynamic — material is moving through interconnected unit operations, residence-time distribution matters, and a disturbance at the feeder is visible at the tablet press minutes later. Q13 expects the control strategy to describe how disturbances are detected, propagated and either corrected in real time or used to divert affected material.

Residence-time distribution (RTD)

RTD characterises how long material spends in each unit operation and how a tracer (or a deviation) spreads. RTD modelling is used to predict which physical product is affected when a disturbance occurs upstream and to design the diversion logic. Q13 treats the RTD model as part of the control strategy; significant changes to RTD-affecting equipment or parameters trigger requalification.

Diverted material

Diverted material is product physically removed from the stream because the control strategy detected it might not meet specification — for example, during start-up, after a feed disturbance, or when a PAT measurement is out of trend. Diverted material is non-batch by definition, must be physically segregated, and is either reworked under change control or destroyed. The batch record documents the diversion event, the affected mass, and the disposition.

Q13 does not change the principles of process validation in ICH Q8 / Q11 or FDA's 2011 Process Validation guidance. PPQ for a CM line is typically performed by running the line at the planned commercial conditions for a defined duration under a PPQ protocol — the 'three batch' convention is not mandated and is often replaced by a justified duration that covers the expected sources of variability.

Real-time release testing (RTRT) is not required by Q13 but is a natural fit. With validated PAT (NIR for blend uniformity, Raman for content uniformity, vision for tablet defects, in-line dissolution surrogates), some or all of the finished-product release tests can be replaced with in-process measurements approved as part of the control strategy. RTRT requires a higher initial development investment and explicit regulatory agreement at filing.

FDA adopted Q13 in March 2023, withdrawing its 2019 draft 'Quality Considerations for Continuous Manufacturing' in favour of the ICH text. EMA adopted Q13 in April 2023; PMDA also in 2023. CDER's Emerging Technology Program (ETP) and CDER's CM Program continue to be the recommended pre-submission engagement route for first-of-a-kind CM filings; CDRH and EMA's Innovation Task Force play equivalent roles for device-combination and EU first filings.

Inspections of CM facilities use the same regulatory framework as batch — 21 CFR 211 / EU GMP — but inspectors will probe the batch definition, the RTD justification, the diversion logic, PAT method validation, and the response to disturbance events captured during the inspection window. Expect to be asked to show a real diversion event end-to-end during a PAI.

CM is not a universal upgrade. It pays off when demand is high and stable enough to justify dedicated capacity, when product quality benefits from tighter process control (e.g., highly potent APIs, narrow-band assays), when batch-to-batch changeover dominates cost, or when development speed matters (CM lines scale by run-time, not equipment). It is a poor fit for low-volume, high-mix lines that need rapid changeover between products with very different formulations.